Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a biopharmaceutical company focused on precision medicines, and its news flow reflects the transition from a clinical-stage organization to a commercial-stage company. Recent announcements highlight full FDA approval and commercial launch of PAPZIMEOS (zopapogene imadenovec-drba), which the company describes as the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). News items detail how PAPZIMEOS was discovered and designed using Precigen’s AdenoVerse platform and how it is being prescribed nationwide in the United States.
Investors and observers following PGEN news will see updates on PAPZIMEOS commercialization, including patient hub enrollment, payer coverage across private health plans and government programs, manufacturing and supply chain arrangements, and engagement with major medical centers and community practices. The company also issues news on long-term clinical data for PAPZIMEOS, emphasizing durable complete responses, reductions in surgery rates, and safety outcomes presented at medical meetings and in peer-reviewed publications.
Beyond PAPZIMEOS, Precigen’s news coverage includes pipeline developments such as progress in Phase 2 trials for PRGN-2009 in HPV-associated cancers and updates on PRGN-3006, an investigational UltraCAR-T therapy for acute myeloid leukemia and myelodysplastic syndromes. Financial results releases and related press statements provide context on capital resources, non-dilutive financing arrangements, preferred stock transactions, and the company’s expectations regarding funding operations through a projected cash flow break-even point.
Visitors to the PGEN news page can expect regular disclosures on regulatory milestones, conference presentations, investor webcasts, and business updates that illustrate how Precigen is advancing its precision medicine strategy and commercial execution around PAPZIMEOS and its broader pipeline.
Precigen, Inc. (Nasdaq: PGEN) will release its fourth quarter and full year 2020 financial results after market close on March 1, 2021. A conference call is scheduled for 4:30 PM ET that day to discuss the results and provide a business update. Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021. The company is focused on advancing gene and cell therapies targeting serious diseases, with ongoing clinical trials and a commitment to innovation in therapeutics.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 12, 2021, at 11:30 AM ET. Investors can access the live webcast through Precigen's website in the Events & Presentations section. Precigen focuses on innovative gene and cell therapies targeting serious diseases, with an emphasis on immuno-oncology, autoimmune disorders, and infectious diseases. For more information, visit www.precigen.com.
Precigen (Nasdaq: PGEN) announced the successful closing of its public offering of common stock, selling 17,250,000 shares at $7.50 each, including an exercised option for 2,250,000 shares. The offering generated approximately $129.4 million in gross proceeds before expenses. Wells Fargo Securities and Stifel served as joint book-running managers, and the offering was made under an effective shelf registration statement. Precigen aims to advance gene and cell therapies in immuno-oncology and other areas.
Precigen, Inc. (PGEN) announced a public offering of 15 million shares at $7.50 per share, generating approximately $112.5 million in gross proceeds. The underwriters have a 30-day option to purchase an additional 2.25 million shares. The offering, expected to close on January 26, 2021, will fund clinical and preclinical product development, working capital, and other corporate purposes. Wells Fargo Securities and Stifel are joint book-running managers.
Precigen, a biopharmaceutical company (Nasdaq: PGEN), has initiated an underwritten public offering of its common stock, granting underwriters a 30-day option for additional shares. The offering, subject to market conditions, will be conducted under an effective shelf registration statement. The offering details, including size and terms, will be disclosed in a preliminary prospectus supplement to be filed with the SEC. Wells Fargo Securities and Stifel are the joint book-running managers for this offering.
On January 13, 2021, Precigen (Nasdaq: PGEN) presented its clinical achievements and goals at the 39th Annual J.P. Morgan Healthcare Conference. Highlights included updates on PRGN-3005 and PRGN-3006 UltraCAR-T, alongside the new UltraCAR-T library approach aimed at personalized cancer therapies. Preliminary data from the Phase I/II study of PRGN-2009 for treating HPV-associated cancers was shared, indicating a strong immune response in patients. The company also announced advancements in other AdenoVerse immunotherapies targeting RRP and HBV, emphasizing its commitment to innovative therapies amidst COVID-19 challenges.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 PM ET. She will also take part in a panel discussion on precision medicine at the H.C. Wainwright BioConnect 2021 Conference on the same day at 12:00 PM ET. Live webcasts are available on Precigen’s website. The company focuses on advancing gene and cell therapies, addressing major health challenges.
On January 5, 2021, Precigen (Nasdaq: PGEN) announced FDA clearance for its IND application to start a Phase I clinical trial for PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11. This trial aims to evaluate the safety and tolerability of PRGN-2012, which utilizes Precigen's proprietary gorilla adenovector technology. The study will enroll 12 patients to assess the treatment's efficacy following surgical removal of the disease. Precigen's collaboration with the NCI aims to address unmet medical needs in RRP patients.
Precigen (Nasdaq: PGEN) held a virtual R&D event on Dec. 15, 2020, showcasing significant advancements in its clinical pipeline. Key updates include:
- PRGN-3005 UltraCAR-T: First clinical data reported with promising results in ovarian cancer showing 50% tumor regression among patients.
- PRGN-3006 UltraCAR-T: Positive data in acute myeloid leukemia (AML) with effective treatment responses.
- AG019 ActoBiotics: Demonstrated safety and potential in stabilizing C-peptide levels in Type 1 diabetes patients.
These results mark critical milestones for the company, indicating progress in innovative gene and cell therapies.
Precigen, a biopharmaceutical company (Nasdaq: PGEN), announced a virtual event on December 15, 2020, at 11:00 AM ET, to update stakeholders on its clinical pipeline. The event will feature data from key programs, including PRGN-3005 and PRGN-3006 UltraCAR-T, as well as AG019 ActoBiotics. Executives and leading investigators will participate, presenting advancements in the company's innovative gene and cell therapies targeting serious diseases. Registration is available via the investor relations website.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
